ARTICLES COVERED THIS WEEK  
 
STUDY 1:
Ong M et al (starts at 5:12). Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: a retrospective study. J Am Acad Dermatol. 2023 Oct 13:S0190-9622(23)02976-6. 
 
Sanabria et al. Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022 May 18;
 
Jimenez-Cauhe J et al. Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil. J Am Acad Dermatol. 2022 Dec;87(6):e235-e237
 
STUDY 2: 
Imhof R et al (starts at 16:35). Safety and tolerability of low dose oral minoxidil monotherapy in female pattern hair loss: A retrospective review with longitudinal ambulatory blood pressure monitoring. JAAD Int. 2023 Aug 12:13:50-52.
 
Ramos PM et al.  Minoxidil 1 mg versus minoxidil 5 % topical solution for the treatment of female-pattern hair loss: A randomized clinical trial. J Am Acad Dermatol Jan 2020;82(1):252-253.
 
STUDY 3: 
Jimenez-Cauhe J  et al (starts at 24:27). Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients. Actas Dermosifiliogr. 2023 Aug 29:S0001-7310(23)00679-8.
 
Vano-Galvan S et al. Safety of  low dose oral  minoxidil for hair loss: A multicenter study of 1404 patients. JAAD 2021; 84: 1644-51.
 
Sanabria B et al. Adverse effects of low dose oral minoxidil for
androgenetic alopecia in 435 patients. JAAD 2021; 84: 1175-78.
 
 
ARITCLES COVERED NEXT WEEK (PREVIEW)
 
Cook M et al. Use of low-level light therapy in management of central centrifugal cicatricial alopecia: A case series of four patients. Photodermatol Photoimmunol Photomed. 2023 Aug 23.
 
Workman K and Kindred C. Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib. JAAD Case Rep. 2023 Jul 28:39:109-111